不可逆电穿孔治疗紧邻膈肌的肝细胞癌：一项前瞻性单中心研究。
Irreversible Electroporation for Hepatocellular Carcinoma Abutting the Diaphragm: A Prospective Single-center Study.
作者信息
Ma Yangyang, Chen Zhixian, Liang Bing, Li Rongrong, Li Jianyu, Li Zhonghai, Lin Mao, Niu Lizhi
机构信息
Central Laboratory, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou, Guangdong, China.
Department of Oncology, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou, Guangdong, China.
出版信息
J Clin Transl Hepatol. 2022 Apr 28;10(2):190-196. doi: 10.14218/JCTH.2021.00019. Epub 2021 Aug 10.
BACKGROUND AND AIMS
Irreversible electroporation (IRE) is an emerging local ablation therapy which may be effective for unresectable tumors. This study aimed to evaluate the safety and efficacy of percutaneous IRE in the treatment of hepatocellular carcinoma (HCC) abutting the diaphragm.
METHODS
A total of 26 participants with 39 tumors abutting the diaphragm were prospectively evaluated between July 2015 and September 2018. Complications associated with IRE were recorded, and the survival benefit of IRE was analyzed. The factors associated with time to local tumor progression (LTP) were analyzed using univariate and multivariate Cox regression models.
RESULTS
No major complications or treatment-related deaths occurred. The technical success rate was 96.2% (25/26) and complete ablation rate was 92.3% (36/39). The median follow-up period was 16.7 months (range: 3.0-43.0 months), the LTP occurred in 15.2% of tumors and median time to LTP was 20.4 months. Overall, tumor size (hazard ratio: 1.24 [95% confidence interval: 0.38, 3.81], =0.03) was the only factor associated with time to LTP.
CONCLUSIONS
This study shows for the first time that percutaneous IRE is a safe and effective ablation technology for HCC abutting the diaphragm.
背景与目的
不可逆电穿孔（IRE）是一种新兴的局部消融治疗方法，可能对不可切除的肿瘤有效。本研究旨在评估经皮IRE治疗紧贴膈肌的肝细胞癌（HCC）的安全性和有效性。
方法
2015年7月至2018年9月期间，对26例患有39个紧贴膈肌肿瘤的参与者进行了前瞻性评估。记录与IRE相关的并发症，并分析IRE的生存获益。使用单因素和多因素Cox回归模型分析与局部肿瘤进展（LTP）时间相关的因素。
结果
未发生重大并发症或与治疗相关的死亡。技术成功率为96.2%（25/26），完全消融率为92.3%（36/39）。中位随访期为16.7个月（范围：3.0 - 43.0个月），15.2%的肿瘤发生LTP，LTP的中位时间为20.4个月。总体而言，肿瘤大小（风险比：1.24 [95%置信区间：0.38, 3.81]，P = 0.03）是与LTP时间相关的唯一因素。
结论
本研究首次表明，经皮IRE是一种治疗紧贴膈肌的HCC的安全有效的消融技术。
Zotero 插件